Skip to content

Study · Animal study (in vivo) · mouse · 2024

2 results

Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.

McKimpson WM, Spiegel S, Mukhanova M, Kraakman M, Du W, Kitamoto T, Yu J, Deng Z, Pajvani U, Accili D

The Journal of cell biology3 Jul 2024Cited by 1 (Europe PMC)

PMID38958606 (opens in a new tab)PMCIDPMC11222742 (opens in a new tab)DOI10.1083/jcb.202305093 (opens in a new tab)PepBankPUB-38958606
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In calorie-restricted mice, GHRP‑6 reversed the phenotypic effects of calorie restriction.

    In plain wordsIn mice, GHRP‑6 reversed the reported effects of calorie restriction.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedCalorie restriction phenotype
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The Notch inhibitor PF-03084014 or ghrelin receptor antagonist GHRP-6 reversed the phenotypic effects of calorie restriction in mice.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, tirzepatide expanded ghrelin-positive cells.

    In plain wordsIn mice, tirzepatide increased the number of ghrelin-positive cells.

    Peptide
    Tirzepatide
    Outcome
    IncreaseGhrelin-positive cell abundance
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide additionally expanded ghrelin+ cells in mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.